Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer

This publication has 15 references indexed in Scilit:

• Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)
  Journal of Urology, 1993
• The Management of Carcinoma of the Prostate after Failed Primary Therapy
  British Journal of Urology, 1993
• Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo
  The Prostate, 1992
• High‐dose Medroxyprogesterone Acetate versus Estramustine in Therapy‐resistant Prostatic Cancer: A Randomised Study
  British Journal of Urology, 1991
• Estramustine Phosphate in Secondary Hormone-Resistant Carcinoma of the Prostate
  European Urology, 1990
• Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.
  The Journal of cell biology, 1988
• Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancer
  Urology, 1988
• Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
  Journal of Clinical Oncology, 1985
• Treatment of Stage D Hormone-Resistant Carcinoma of the Prostate with Estramustine Phosphate
  Journal of Urology, 1979
• Treatment of Advanced Prostatic Carcinoma with Estramustine Phosphate (Estracyt®)
  Scandinavian Journal of Urology and Nephrology, 1977